-
公开(公告)号:US20230132378A9
公开(公告)日:2023-04-27
申请号:US17827041
申请日:2022-05-27
发明人: Graham Timmins , Ke Jian Liu , Rong Pan
IPC分类号: A61K31/409 , A61P9/10 , A61K31/437 , A61K31/4439 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/517 , A61K31/5377
摘要: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or at risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.
-
公开(公告)号:US20220288025A1
公开(公告)日:2022-09-15
申请号:US17827041
申请日:2022-05-27
发明人: Graham Timmins , Ke Jian Liu , Rong Pan
IPC分类号: A61K31/409 , A61P9/10 , A61K31/437 , A61K31/4439 , A61K31/47 , A61K31/4706 , A61K31/4709 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/517 , A61K31/5377
摘要: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or at risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.
-
公开(公告)号:US20210128527A1
公开(公告)日:2021-05-06
申请号:US16770438
申请日:2018-12-07
发明人: Graham Timmins , Ke Jian Liu , Rong Pan
IPC分类号: A61K31/409 , A61K31/4439 , A61K31/47 , A61K31/4709 , A61K31/517 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/4706 , A61K31/496 , A61K31/437 , A61P9/10
摘要: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.
-
-